对口服抗凝剂直接管理的基于人口的方法的评估
Nghi Ha1, Erin Mouland1, Elizabeth Renner1
1Pharmacy Innovations & Partnerships, Michigan Medicine, Ann Arbor, MI, USA.
概括
该DOAC仪表板有效地识别需要直接口服抗凝剂调整的患者. 该系统有助于管理大量患者群体的药物安全性和有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 医疗信息学 医疗信息学
- 患者安全 患者安全
背景情况:
- 越来越多地使用直接口服抗凝剂 (DOACs),需要更新护理模式.
- 在一个学术医疗中心实施了DOAC仪表板,以监测服用这些药物的患者.
- 这个仪表板跟踪需要根据临床因素对剂量或治疗调整进行评估的患者.
研究的目的:
- 描述DOAC仪表板的最初实施情况.
- 评估由仪表板触发的干预措施的有效性.
- 评估一个多学科的方法来管理患者在DOACs.
主要方法:
- 从2019年8月到2022年1月进行了一项回顾性描述性研究.
- 集成到电子健康记录中的DOAC仪表板被用于识别患者.
- 主要结果包括处理的警报数量和所需的干预措施;次要结果是干预措施的实施率.
主要成果:
- 在DOAC仪表板上,在基线确定了10,912名患者,产生了5,038个警报.
- 药剂师处理了1796个警报,包括药物相互作用和不适当剂量的关键警报.
- 在需要干预的关键警报中,有88%是由处方临床医生实施的.
结论:
- DOAC仪表板是识别需要DOAC剂量或治疗修改的患者的有效工具.
- 该系统支持直接口服抗凝剂治疗的积极管理.
- 仪表板有助于更高效,更安全地对抗凝血管理进行管理.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Analysis of Population Pharmacokinetic Data
254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Pharmacovigilance
830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830
Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616


